Home  /  Resource Library  /  Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Brentuximab Vedotin and AVD followed by ISRT is well tolerated, without significant pulmonary toxicity. Brentuximab Vedotin and AVD followed by ISRT is an effective therapy for unfavorable risk early stage HL, including bulky disease.